Berlin, Germany
Berlin, Germany

MagForce Nanotechnologies AG is a German biotechnology company focusing on cancer treatment. It is a world's leading company in treating cancer cells with nanotechnology-based therapy. The company is led by CEO Ben J. Lipps. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

LUXEMBOURG and BERLIN, GERMANY / ACCESSWIRE / August 8, 2017 / Patients who suffer from the most aggressive type of brain cancer, glioblastoma, will soon have broader access to a new form of treatment thanks to financing by the European Investment Bank ("EIB"). The EIB and German medical device company, MagForce, listed in the Scale segment of the Frankfurt Stock Exchange (FRA: MF6; ISIN: DE000A0HGQF5; XETRA: MF6), signed a financing agreement which will allow the company to borrow up to EUR 35 million over the coming three years, subject to achieving a set of agreed performance criteria. The transaction with MagForce was made possible by the European Fund for Strategic Investments ("EFSI"). EFSI is the central pillar of the Investment Plan for Europe, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy. MagForce has developed NanoTherm therapy, a new approach to the local treatment of solid tumors. The method is based on the principle of introducing magnetic nanoparticles directly into a tumor and then heating them in an alternating magnetic field. Depending on the duration of treatment and the temperatures achieved within the tumor, the tumor cells are either irreparably damaged or sensitized for additional chemo or radiotherapy. This approach makes it possible to combat the tumor from within while sparing surrounding healthy tissue. The side effects of the treatment are significantly lower than those in the standard methods currently used. In addition, the NanoTherm therapy displays a high degree of efficacy proven in clinical studies. It received regulatory approval for brain cancer in Europe, and patients are already successfully treated in Germany. EIB financing will support NanoTherm's Europe-wide roll-out for brain cancer. Furthermore, the facility will support European and global approval for prostate cancer - another oncological condition, which can be treated with NanoTherm therapy. In addition, MagForce is working on next generation nanoparticles, which will not only be able to generate heat but can also be used as drug transport mechanisms. "More than 20 million people worldwide are expected to live with cancer in the year 2030 - a 50% increase from the levels of 2012," said Ambroise Fayolle, Vice-President of the EIB and responsible for operations in Germany. "The therapy developed by MagForce has the potential to considerably ease the burden for some of those patients, and I am proud that EIB backing will actually help save people's lives. The EU bank provides long-term and stable capital support to the company's R&D which will enable MagForce to accelerate the market launch of new treatments. It's this type of support for innovative companies that is crucial to strengthening Europe's competitiveness." Ben Lipps, Chief Executive Officer of MagForce, commented, "We are honored that MagForce is backed by the European Fund for Strategic Investments. The loan will significantly enhance our financial standing and help us to roll-out MagForce's NanoTherm therapy across Europe. It will also support the development and global commercialization of prostate cancer solutions and MagForce's next generation NanoTherm." European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, said, "The European Commission is committed to promoting investment in research and innovation. I am delighted that, with today's agreement, the Plan is contributing to the development of sophisticated new treatments for cancer patients. This is a very tangible example of the powerful impact EU support for investments can bring about." The EIB is the long-term lending institution of the EU. It is owned by and represents the interests of the European Union countries. The Bank makes long-term finance available for sound investment in order to contribute towards EU policy goals. The EIB works closely with other EU institutions to implement EU policy. Founded in 1997 and based in Berlin, MagForce AG is a pioneer in the field of nanomedicine focused on oncology.Its objective is to establish a novel cancer therapy alongside conventional treatment methods such as surgery, radiation, and chemotherapy. The company's proprietary NanoTherm therapy enables the targeted treatment of solid tumors via heat generated directly in the tumor and activated through superparamagnetic nanoparticles. MagForce was the first company in the world to receive European approval for a medical product using nanoparticles. It has 26 employees, plus a production company with another 14 staff members. The Investment Plan for Europe, the so-called Juncker Plan, is one of European Commission President Jean-Claude Juncker's top priorities. It focuses on boosting European investments to create jobs and growth by making smarter use of new and existing financial resources, removing obstacles to investment and providing visibility and technical assistance to investment projects. The European Fund for Strategic Investments (EFSI) is the central pillar of the Investment Plan. It allows the EIB to invest in more, often riskier, projects. EFSI is already showing concrete results. The projects and agreements approved for financing under EFSI so far are expected to mobilize EUR 225bn in total investments and support some 445 000 SMEs across all 28 Member States. The latest EFSI figures by sector and by country are available here. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates," or "will." Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. LUXEMBOURG and BERLIN, GERMANY / ACCESSWIRE / August 8, 2017 / Patients who suffer from the most aggressive type of brain cancer, glioblastoma, will soon have broader access to a new form of treatment thanks to financing by the European Investment Bank ("EIB"). The EIB and German medical device company, MagForce, listed in the Scale segment of the Frankfurt Stock Exchange (FRA: MF6; ISIN: DE000A0HGQF5; XETRA: MF6), signed a financing agreement which will allow the company to borrow up to EUR 35 million over the coming three years, subject to achieving a set of agreed performance criteria. The transaction with MagForce was made possible by the European Fund for Strategic Investments ("EFSI"). EFSI is the central pillar of the Investment Plan for Europe, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy. MagForce has developed NanoTherm therapy, a new approach to the local treatment of solid tumors. The method is based on the principle of introducing magnetic nanoparticles directly into a tumor and then heating them in an alternating magnetic field. Depending on the duration of treatment and the temperatures achieved within the tumor, the tumor cells are either irreparably damaged or sensitized for additional chemo or radiotherapy. This approach makes it possible to combat the tumor from within while sparing surrounding healthy tissue. The side effects of the treatment are significantly lower than those in the standard methods currently used. In addition, the NanoTherm therapy displays a high degree of efficacy proven in clinical studies. It received regulatory approval for brain cancer in Europe, and patients are already successfully treated in Germany. EIB financing will support NanoTherm's Europe-wide roll-out for brain cancer. Furthermore, the facility will support European and global approval for prostate cancer - another oncological condition, which can be treated with NanoTherm therapy. In addition, MagForce is working on next generation nanoparticles, which will not only be able to generate heat but can also be used as drug transport mechanisms. "More than 20 million people worldwide are expected to live with cancer in the year 2030 - a 50% increase from the levels of 2012," said Ambroise Fayolle, Vice-President of the EIB and responsible for operations in Germany. "The therapy developed by MagForce has the potential to considerably ease the burden for some of those patients, and I am proud that EIB backing will actually help save people's lives. The EU bank provides long-term and stable capital support to the company's R&D which will enable MagForce to accelerate the market launch of new treatments. It's this type of support for innovative companies that is crucial to strengthening Europe's competitiveness." Ben Lipps, Chief Executive Officer of MagForce, commented, "We are honored that MagForce is backed by the European Fund for Strategic Investments. The loan will significantly enhance our financial standing and help us to roll-out MagForce's NanoTherm therapy across Europe. It will also support the development and global commercialization of prostate cancer solutions and MagForce's next generation NanoTherm." European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, said, "The European Commission is committed to promoting investment in research and innovation. I am delighted that, with today's agreement, the Plan is contributing to the development of sophisticated new treatments for cancer patients. This is a very tangible example of the powerful impact EU support for investments can bring about." The EIB is the long-term lending institution of the EU. It is owned by and represents the interests of the European Union countries. The Bank makes long-term finance available for sound investment in order to contribute towards EU policy goals. The EIB works closely with other EU institutions to implement EU policy. Founded in 1997 and based in Berlin, MagForce AG is a pioneer in the field of nanomedicine focused on oncology.Its objective is to establish a novel cancer therapy alongside conventional treatment methods such as surgery, radiation, and chemotherapy. The company's proprietary NanoTherm therapy enables the targeted treatment of solid tumors via heat generated directly in the tumor and activated through superparamagnetic nanoparticles. MagForce was the first company in the world to receive European approval for a medical product using nanoparticles. It has 26 employees, plus a production company with another 14 staff members. The Investment Plan for Europe, the so-called Juncker Plan, is one of European Commission President Jean-Claude Juncker's top priorities. It focuses on boosting European investments to create jobs and growth by making smarter use of new and existing financial resources, removing obstacles to investment and providing visibility and technical assistance to investment projects. The European Fund for Strategic Investments (EFSI) is the central pillar of the Investment Plan. It allows the EIB to invest in more, often riskier, projects. EFSI is already showing concrete results. The projects and agreements approved for financing under EFSI so far are expected to mobilize EUR 225bn in total investments and support some 445 000 SMEs across all 28 Member States. The latest EFSI figures by sector and by country are available here. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates," or "will." Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.


LUXEMBOURG and BERLIN, GERMANY / ACCESSWIRE / August 8, 2017 / Patients who suffer from the most aggressive type of brain cancer, glioblastoma, will soon have broader access to a new form of treatment thanks to financing by the European Investment Bank ("EIB"). The EIB and German medical device company, MagForce, listed in the Scale segment of the Frankfurt Stock Exchange (FRA: MF6; ISIN: DE000A0HGQF5; XETRA: MF6), signed a financing agreement which will allow the company to borrow up to EUR 35 million over the coming three years, subject to achieving a set of agreed performance criteria. The transaction with MagForce was made possible by the European Fund for Strategic Investments ("EFSI"). EFSI is the central pillar of the Investment Plan for Europe, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy. MagForce has developed NanoTherm therapy, a new approach to the local treatment of solid tumors. The method is based on the principle of introducing magnetic nanoparticles directly into a tumor and then heating them in an alternating magnetic field. Depending on the duration of treatment and the temperatures achieved within the tumor, the tumor cells are either irreparably damaged or sensitized for additional chemo or radiotherapy. This approach makes it possible to combat the tumor from within while sparing surrounding healthy tissue. The side effects of the treatment are significantly lower than those in the standard methods currently used. In addition, the NanoTherm therapy displays a high degree of efficacy proven in clinical studies. It received regulatory approval for brain cancer in Europe, and patients are already successfully treated in Germany. EIB financing will support NanoTherm's Europe-wide roll-out for brain cancer. Furthermore, the facility will support European and global approval for prostate cancer - another oncological condition, which can be treated with NanoTherm therapy. In addition, MagForce is working on next generation nanoparticles, which will not only be able to generate heat but can also be used as drug transport mechanisms. "More than 20 million people worldwide are expected to live with cancer in the year 2030 - a 50% increase from the levels of 2012," said Ambroise Fayolle, Vice-President of the EIB and responsible for operations in Germany. "The therapy developed by MagForce has the potential to considerably ease the burden for some of those patients, and I am proud that EIB backing will actually help save people's lives. The EU bank provides long-term and stable capital support to the company's R&D which will enable MagForce to accelerate the market launch of new treatments. It's this type of support for innovative companies that is crucial to strengthening Europe's competitiveness." Ben Lipps, Chief Executive Officer of MagForce, commented, "We are honored that MagForce is backed by the European Fund for Strategic Investments. The loan will significantly enhance our financial standing and help us to roll-out MagForce's NanoTherm therapy across Europe. It will also support the development and global commercialization of prostate cancer solutions and MagForce's next generation NanoTherm." European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, said, "The European Commission is committed to promoting investment in research and innovation. I am delighted that, with today's agreement, the Plan is contributing to the development of sophisticated new treatments for cancer patients. This is a very tangible example of the powerful impact EU support for investments can bring about." The EIB is the long-term lending institution of the EU. It is owned by and represents the interests of the European Union countries. The Bank makes long-term finance available for sound investment in order to contribute towards EU policy goals. The EIB works closely with other EU institutions to implement EU policy. Founded in 1997 and based in Berlin, MagForce AG is a pioneer in the field of nanomedicine focused on oncology.Its objective is to establish a novel cancer therapy alongside conventional treatment methods such as surgery, radiation, and chemotherapy. The company's proprietary NanoTherm therapy enables the targeted treatment of solid tumors via heat generated directly in the tumor and activated through superparamagnetic nanoparticles. MagForce was the first company in the world to receive European approval for a medical product using nanoparticles. It has 26 employees, plus a production company with another 14 staff members. The Investment Plan for Europe, the so-called Juncker Plan, is one of European Commission President Jean-Claude Juncker's top priorities. It focuses on boosting European investments to create jobs and growth by making smarter use of new and existing financial resources, removing obstacles to investment and providing visibility and technical assistance to investment projects. The European Fund for Strategic Investments (EFSI) is the central pillar of the Investment Plan. It allows the EIB to invest in more, often riskier, projects. EFSI is already showing concrete results. The projects and agreements approved for financing under EFSI so far are expected to mobilize EUR 225bn in total investments and support some 445 000 SMEs across all 28 Member States. The latest EFSI figures by sector and by country are available here. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates," or "will." Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.


The invention relates to a computer-aided simulation tool, in particular to computer-aided simulation methods, for providing assistance in the planning of thermotherapy, and to suitably configured computer equipment. The thermotherapy comprises hyperthermic treatment of a tumour volume within a volume of a human body. The hyperthermic treatment comprises the application of a magnetic field within a treatment volume by means of a magnetic field applicator. In at least one depot volume, thermal energy can be introduced by means of magnetic, paramagnetic and/or superparamagnetic nanoparticles deposited in the body, by power absorption in the applied magnetic field. Field strength values and optionally calculated temperature distributions are provided for assisting the user in the planning of the thermotherapy.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.2-1 | Award Amount: 10.28M | Year: 2013

Microbubbles (MBs) are used as contrast agent in ultrasound (US) imaging for a variety of tumours while little has been done for glioblastomas, a rare cancer. Intraoperative Contrast-Enhanced US-imaging (CEUS) using lipidic MBs hold promises in increasing extent of resection of such tumors. Furthermore, MBs gained recently interest as a delivery system for drugs. We will develop a new generation of multimodal MBs, acting simultaneously as contrast agent for Magnetic Resonance Imaging (MRI), CEUS and intra-operative fluorescence for multimodal real-time image-guided resection of glioblastomas. We plan to transform MBs by replacing air with perfluorcarbon gas and/or attaching super-paramagnetic-iron-oxide nanoparticles for MRI visualization. We will also engineer MBs with RGD-motif to adhere selectively to pathological endothelial integrins and with near-infrared fluorophores for simultaneous US deep tissue imaging and direct microscopic tumour visualization to maximize resection. A software will be developed for integration of preoperative MRI, intraoperative US and microscopic imaging. We will focus on lipidic and polymeric MBs. Lipidic MBs are approved for clinical use; therefore, once modified, more easily translatable into clinical applications to reach a feasibility study on patients. In addition, we will improve multifunctional, polymer-based MBs. Multifunctional-stabilized-polymer-MBs are more stable and more versatile to be complexed with different molecules or nanoparticles as compared to lipidic Mbs and will be designed as a platform for delivering standard and/or experimental chemotherapeutic drugs to the tumour, acting as an innovative way for local targeting and delivering any kind of agent to a specific target, in a safe and controlled fashion. This would be a big step forward in the field of personalized medicine, moving standard MG image-guided treatment towards more effective, safer, molecular-based tailored interventions to specific patients.


The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.


Patent
MagForce | Date: 2014-05-15

Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.


The present invention relates to a method for producing a suspension of agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein an aqueous suspension of magnetic metal nanoparticles is incubated with alkoxysilane, wherein the incubation is carried out essentially in the absence of an organic solvent. The present invention further relates to suspension of agglomerates of magnetic alkoxysilane-coated metal containing nanoparticles obtainable by the method of the present invention and to a composition comprising agglomerates of magnetic alkoxysilane-coated metal nanoparticles, wherein the agglomerates have an average size of 30 to 450 nm, preferably of 50 to 350 nm and especially of 70 to 300 nm as determined by light scattering.


Patent
MagForce | Date: 2015-09-09

The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: NMP-2008-1.1-1 | Award Amount: 4.86M | Year: 2009

The aim of this project is the assembly and the fabrication of a new generation of multifunctional nanostructures for performing combined hyperthermia and controlled drug release, specifically targeted to cancer cells. The magnetic nanocontainers we intend to develop can perform at the same time cell recognition, hyperthermia treatment, and, as a consequence of the heat and /or cell environment stimuli, the release of drug with high selectivity for ovarian carcinoma. These multifunctional tasks are made possible due to the inclusion of three main components: a) the magnetic nanoparticles, allowing detection by MRI, cancer treatment by hyperthermia and providing stimuli for drug release; b) the nanocontainers, which allow for drug encapsulation and protection from degradation, facilitate the release of the drug upon application of an external stimulus, such as heat, or an internal one, such as the acidic pH of the tumour cells; c) the antibody fragments attached to the surface of the magnetic nanocontainers to deliver them selectively to the ovarian cancer cells. The individual building blocks and their assemblies will be characterized with respect to physical, chemical, and biological features, followed by dissemination of the newly acquired knowledge. Cell culture experiments will allow to understand the performance of such nano-tools in vitro. Directed towards application in patients, in vivo animal studies will be carried out on the most successful magnetic nanocontainers. The objectives of this proposal cover a wide range of scientific fields, hence a truly interdisciplinary collaboration between chemists, physicists, and biologists is required. To this end, we propose a european network collaboration between academic partners, who will take care of the development of new solutions for nanofabrication, and industrial partners implied in the field of the proposed application who will evaluate/develop the materials and act as advisors for risks arising during the project.


News Article | March 2, 2017
Site: www.accesswire.com

BERLIN, GERMANY, AND NEVADA / ACCESSWIRE / March 2, 2017 / MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published its first Shareholder Letter 2017: Since the publication of our last Shareholder Letter, we have continued our joint efforts on both of our defined paths to create additional shareholder value: Path 2: Treatment of intermediate risk prostate cancer in the USA We are pleased to give you an interim update on the respective developments. MagForce AG is continuing to expand the commercialization of its innovative NanoTherm(R) therapy. We successfully installed NanoActivator(R) devices in 2014 and 2015 in Germany to assist the neurosurgeons and radiologists as they became familiar with our NanoTherm(R) therapy and its applicability. In their quest to improve patient care, the neurosurgeons applying NanoTherm(R) therapy to the treatment of brain tumors continue to find additional medical benefits when NanoTherm(R) therapy is incorporated into their usual treatment regimen. Such a positive finding for example was described by Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster and part of the team of Prof. Dr. med. Walter Stummer, Director of the Department of Neurosurgery at the University Hospital Münster and President of the German Neurosurgical Society (DGNC), as described in our press release as of December 2, 2016. Since the last Shareholder Letter we presented at the following conferences and congresses: MagForce's participation in these conferences and congresses increases the awareness of our unique therapy within the main target groups, such as patient advocacy groups, patients, their relatives, caregivers, and the medical community. We increasingly receive positive feedback from patients regarding their experiences with our NanoTherm(R) therapy. These examples, one of which we are showing in a new video on our website http://www.magforce.de/en/home.html are an important driver for the commercialization of our innovative therapy. During 2016, we have streamlined the implementation of the cross-border reimbursement process, however, due to the aggressiveness of glioblastoma, there is a limited time interval to achieve treatment. In order to give patients the benefit from our NanoTherm(R) treatment, we will continue to increase the medical awareness of the value of NanoTherm(R) therapy to encourage patients and neurosurgeons to consider NanoTherm(R) therapy earlier following the diagnosis of their tumor status. Further, we have developed a European roll-out plan, anticipating treatment centers in selected European countries to allow patient treatment in their home countries. From this approach we expect advantages in the areas of reimbursement and timely availability of NanoTherm(R) therapy. At the same time, we are in the process of obtaining domestic reimbursement for NanoTherm(R) therapy in Germany and we are preparing the same for those selected countries in the EU where MagForce has the CE Mark for the treatment of brain tumors. Our commercial and medical teams have identified the respective countries and clinics which qualify as NanoTherm(R) treatment centers. Based on the very gratifying medical results, management is confident that the European expansion starting in 2017, when combined with reimbursement approval in these countries, will significantly speed up revenue and profit generation in Europe. Treatment of intermediate risk prostate cancer in the USA: MagForce USA, Inc. in 2015, filed an Investigational Device Exemption (IDE) with the USA Food and Drug Administration (FDA) for NanoTherm(R) therapy to treat Intermediate Risk Prostate Cancer. Our objective with this early filing was to obtain FDA guidance as to their required pre-clinical studies to allow a pivotal clinical evaluation with our innovative and unknown NanoTherm(R) therapy. During 2016, MagForce USA repeated and updated its pre-clinical studies, which were previously conducted in Germany approximately ten years ago, at the recommendation of the FDA. MagForce USA repeated all of the previous biocompatibility studies designed to assess the toxicity and possible migration of MagForce's nanoparticles once instilled into the prostate. These studies again confirmed the lack of toxicity and lack of migration of the nanoparticles. The results of these pre-clinical studies and the proposed clinical trial protocol were submitted to the FDA in late fourth quarter, 2016. An in-person follow-up meeting with FDA representatives was held in early January, 2017 to discuss MagForce's submissions and identify required clarification. This meeting was again very productive and MagForce believes we can successfully address their questions. While we are now approximately three months behind our schedule, we are still confident and will make every effort to achieve our original targets in terms of market entry and commercialization of NanoTherm(R) therapy in the USA - which is projected for early 2018. The key to achieving our goals is to continue to establish our clinical treatment sites and obtain the necessary approvals to treat patients. After having announced Seattle Washington in 2015 for pre-clinical and clinical studies, we have now identified a second planned site to exclusively participate in the pivotal clinical studies. In addition to our lead site at The University of Washington in Seattle, Washington, our second site is now located at CHRISTUS Santa Rosa Hospital - Medical Center in San Antonio, Texas. Ian M. Thompson Jr., MD, our Co-Principle Investigator, has been newly appointed as President of CHRISTUS Santa Rosa Hospital - Medical Center among his many responsibilities. This clinical site will encompass both a clinical office and the NanoActivator(R) treatment center. CHRISTUS Santa Rosa Health is an international Catholic, faith-based, not-for-profit health system, and comprised of over 500 services and facilities, including more than 50 hospitals and long-term facilities and 275 clinics and outpatient centers. CHRISTUS Santa Rosa's services can be found in over 100 cities in the United States, Chile, Mexico and Colombia, and employs over 40,000 associates and has more than 10,000 physicians on medical staff. We are very excited to work with the team of CHRISTUS Santa Rosa Hospital - Medical Center with its exceptional experience and knowledge. This partnership also gives MagForce the potential to utilize CHRISTUS Santa Rosa's established network once the FDA approval is obtained and our partners at CHRISTUS Santa Rosa Hospital - Medical Center are satisfied with the treatment regimen. MagForce's management is pursuing non/low dilutive financing options to reach our European expansion goals. In addition, in order to bolster liquidity and facilitate new product development beyond 2017, we have issued a three-year convertible note. Product development includes laying the groundwork for expanding MagForce's therapy to additional tumors, like brain metastasis, and to also use our nano-particles as a drug delivery mechanism. The note is in the amount of EUR 5 million, will bear an interest rate at 5% p.a. and have a conversion price at 5,00 EUR/share. The note has been issued to an investment vehicle managed by Lansdowne Partners Austria. Dear Shareholders, we are very grateful for your continuous support of our efforts, and we are very confident that 2017 will turn out to be the best and most defining year in the history of MagForce. About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the new Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com. Get to know our Technology: video (You Tube) Stay informed and subscribe to our mailing list. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. SOURCE: MagForce AG via the EQS Newswire distribution service including Press Releases and Regulatory Announcements

Loading MagForce collaborators
Loading MagForce collaborators